Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition

Toxicology in Vitro

Volumn 28, Issue 4, 2014, Pages 552-561

  Huynh, Thanh Tuan ^a,b   Rao, Yerra Koteswara ^c   Lee, Wei Hwa ^d   Chen, Hsin An ^d   Le, T Do Quyen ^e   Tzeng, David T W ^f   Wang, Liang Shun ^a,d   Wu, Alexander T H ^a   Lin, Yuh Feng ^a   Tzeng, Yew Min ^c   Yeh, Chi Tai ^a,d,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^c CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHO RAY HOSPITAL   (Viet Nam)

^f NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Destruxin B; EMT; HCC; Metastasis; Sorafenib combination; Wnt catenin

Indexed keywords

ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; DESTRUXIN B;

APOPTOSIS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MOLECULAR STRUCTURE; WNT SIGNALING PATHWAY;

EID: 84893741977     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.01.002     Document Type: Article

References (43)

1. Abrams P., Marsh J.W. Current approach to hepatocellular carcinoma. Surg. Clin. North Am. 2010, 90:803-816.
2. Angers S., Moon R.T. Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 2009, 10:468-477.
3. Brunocilla P.R., Brunello F., Carucci P., Gaia S., Rolle E., Cantamessa A., Castiglione A., Ciccone G., Rizzetto M. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med. Oncol. 2013, 30:345.
4. Calvisi D.F., Ladu S., Factor V.M., Thorgeirsson S.S. Activation of β-catenin provides proliferative and invasive advantages in c-myc/TGF-α hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 2004, 25:901-908.
5. Cavelier F., Jacquier R., Mercadier J.L., Verducci J., Traris M., Vey A. Destruxin analogs: variations of the alpha-hydroxy acid side chain. J. Pept. Res. 1997, 50:94-101.
6. Chao P.Z., Chin Y.P., Hsu I.U., Liu C.M., Yu Y.C., Leung T.K., Lee Y.J., Chen C.H., Lin Y.F. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol. In Vitro 2013, 27:1870-1876.
7. Chen H.C., Chou C.K., Sun C.M., Yeh S.F. Suppressive effects of destruxin B on hepatitis B virus surface antigen gene expression in human hepatoma cells. Antiviral Res. 1997, 34:137-144.
8. Chen K.F., Chen H.L., Tai W.T., Feng W.C., Hsu C.H., Chen P.J., Cheng A.L. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 2011, 337:155-161.
9. Dahmani R., Just P.A., Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 2011, 35:709-713.
10. Di Marco V., De Vita F., Koskinas J., Semela D., Toniutto P., Verslype C. Sorafenib: from literature to clinical practice. Ann. Oncol. 2013, 24:ii30-ii37.
11. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
12. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
13. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., Tanabe K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008, 68:2391-2399.
14. Gauthier A., Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol. Res. 2013, 43:147-154.
15. Himmelsbach K., Sauter D., Baumert T.F., Ludwig L., Blum H.E., Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009, 58:1644-1653.
16. Horst D., Chen J., Morikawa T., Ogino S., Kirchner T., Shivdasani R.A. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012, 72:1547-1556.
17. Ibrahim N., Yu Y., Walsh W.R., Yang J.L. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol. Rep. 2012, 27:1303-1311.
18. Ichikawa H., Nakamura Y., Kashiwada Y., Aggarwal B.B. Anticancer drugs designed by mother nature: ancient drugs but modern targets. Curr. Pharm. Des. 2007, 13:3400-3416.
19. Iwatsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., Baba H., Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101:293-299.
20. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
21. Kim D., Rath O., Kolch W., Cho K.H. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 2007, 26:4571-4579.
22. Kim Y.D., Park C.H., Kim H.S., Choi S.K., Rew J.S., Kim D.Y., Koh Y.S., Jeung K.W., Lee K.H., Lee J.S., Juhng S.W., Lee J.H. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008, 23:110-118.
23. Kim H.J., Park S.Y., Park O.J., Kim Y.M. Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Mol. Med. Rep. 2013, 8:282-286.
24. Lachenmayer A., Alsinet C., Savic R., Cabellos L., Toffanin S., Hoshida Y., Villanueva A., Minguez B., Newell P., Tsai H.W., Barretina J., Thung S., Ward S.C., Bruix J., Mazzaferro V., Schwartz M., Friedman S.L., Llovet J.M. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 2012, 18:4997-5007.
25. Laurent-Puig P., Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006, 25:3778-3786.
26. Liu B.L., Tzeng Y.M. Development and applications of destruxins: a review. Biotechnol. Adv. 2012, 30:1242-1254.
27. MacDonald B.T., Tamai K., He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
28. Melet A., Song K., Bucur O., Jagani Z., Grassian A.R., Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv. Exp. Med. Biol. 2008, 615:47-79.
29. Muroi M., Shiragami N., Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem. Biophys. Res. Commun. 1994, 205:1358-1365.
30. Penga K.C., Huanga H.S., Tzeng Y.M., Liu S.Y. Circular dichroism analysis of destruxins from Metarhizium anisopliae. J. Biochem. Biophys. Methods 2005, 62:41-50.
31. Rahbari N.N., Mehrabi A., Mollberg N.M., Muller S.A., Koch M., Buchler M.W., Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. Ann. Surg. 2011, 253:453-469.
32. Rao Y.K., Wu A.T., Geethangili M., Huang M.T., Chao W.J., Wu C.H., Deng W.P., Yeh C.T., Tzeng Y.M. Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem. Res. Toxicol. 2011, 24:238-245.
33. Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn. J. Clin. Oncol. 2011, 41:447-454.
34. Tung E.K., Wong B.Y., Yau T.O., Ng I.O. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PloS one 2012, 7:e36565.
35. Van Malenstein H., Dekervel J., Verslype C., Van Cutsem E., Windmolders P., Nevens F., Van Pelt J. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013, 329:74-83.
36. Villanueva A., Llovet J.M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 2012, 18:1824-1826.
37. Wei W., Chua M.S., Grepper S., So S. Small molecule antagonists of Tcf4/β-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer 2010, 126:2426-2436.
38. Wei P.L., Kuo L.J., Wang W., Lin F.Y., Liu H.H., How T., Ho Y.S., Huang M.T., Wu C.H., Chang Y.J. Silencing of glucose-regulated protein 78 (GRP78) enhances cell migration through the upregulation of vimentin in hepatocellular carcinoma cells. Ann. Surg. Oncol. 2012, 19:S572-S579.
39. White B.D., Chien A.J., Dawson D.W. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012, 142:219-232.
40. Wu C.C., Chen T.H., Liu B.L., Wu L.C., Chen Y.C., Tzeng Y.M., Hsu S.L. Destruxin B isolated from entomopathogenic fungus Metarhizium anisopliae induces apoptosis via a Bcl-2 family-dependent mitochondrial pathway in human nonsmall cell lung cancer cells. Evid. Based Complement. Alternat. Med. 2013, 2013:548929.
41. Yang W., Yan H.X., Chen L., Liu Q., He Y.Q., Yu L.X., Zhang S.H., Huang D.D., Tang L., Kong X.N., Chen C., Liu S.Q., Wu M.C., Wang H.Y. Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008, 68:4287-4295.
42. Yeh C.T., Rao Y.K., Ye M., Wu W.S., Chang T.C., Wang L.S., Wu C.H., Wu A.T., Tzeng Y.M. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol. Appl. Pharmacol. 2012, 261:31-41.
43. Yun M.S., Kim S.E., Jeon S.H., Lee J.S., Choi K.Y. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 2005, 118:313-322.